Home > Chemial News > Pharma News > The price of Merck’s COVID-19 specific drug is 40 times the cost; Fosun Pharma sells its diagnostic segment for nearly 1.6 billion yuan

The price of Merck’s COVID-19 specific drug is 40 times the cost; Fosun Pharma sells its diagnostic segment for nearly 1.6 billion yuan

Echemi 2021-10-11

A course of treatment is 700 dollars! The price of Merck's new crown drug is 40 times the cost. Molnupiravir, an oral new crown drug developed by the US pharmaceutical company Merck & Co., has recently attracted many countries to snap up purchases. After Merck announced that monupivir can significantly reduce the risk of severe hospitalization or death for patients with new coronary pneumonia, Singapore, South Korea, Australia and other countries have placed orders. If approved by regulatory agencies, monupivir will become the first oral antiviral drug for the treatment of COVID-19. Recently, Merck & Co. announced that monupivir, developed in cooperation with its partner Ridgeback Biotherapeutics, has obtained positive interim analysis results in a phase III study of patients with mild or moderate new coronary pneumonia. Patients are taking monupivir. On the 29th day, the proportion of severe hospitalization or death was only 7.3%, which was much lower than 14.1% in the placebo group. The drug can reduce the risk of hospitalization or death by about 50%. In addition, the production cost of monupivir is US$17.74. The US government signed a $1.2 billion contract with Merck to supply 1.7 million courses of medicine at a price of $712, which is 40 times the production cost.


Merck's US plant was approved to produce Johnson & Johnson's new crown vaccine. The European Medicines Agency (EMA) has approved Merck's (MSD) production facility in the United States to produce the new crown vaccine developed by Johnson & Johnson's Janssen. Merck's factory can be put into operation immediately. In March this year, Merck announced the establishment of a partnership with Johnson & Johnson to use its several production bases to help produce single-dose vaccines.


AstraZeneca has submitted an EUA application for the prevention of new coronary symptoms to the US FDA. AstraZeneca has submitted an emergency use authorization (EUA) application for AZD7442 to the US FDA for the prevention of symptomatic new coronary pneumonia. If approved, the long-acting antibody (LAAB) combination-AZD7442 will be the first preventive drug to obtain EUA and be used to prevent symptomatic new coronary pneumonia. Regarding the negotiation of the AZD7442 supply agreement, AstraZeneca is proceeding in an orderly manner with the US government and governments around the world. At the beginning of August, AstraZeneca announced the positive results of the Phase III PROVENT clinical trial, showing that AZD7442 is 77% effective in preventing symptomatic new coronary pneumonia compared with the placebo control group, which is statistically significant.


Fosun Pharma sold two assets in the diagnostics segment for nearly 1.6 billion yuan. Fosun Pharma intends to sell 29% equity of Yaneng Biosciences and 100% equity of Jinshi Medical Inspectorate to the buyer YanengBioscience for nearly 1.6 billion yuan. The proceeds will be mainly used for the follow-up new track layout, product research and development, base construction and market investment of the diagnostic segment , To promote the long-term sustainable development of the diagnostics sector, the transaction company is expected to receive 1.4 billion yuan after-tax income. Yaneng Biological was established in July 2001, registered in Shenzhen. Yaneng Biological and its holding subsidiaries are mainly engaged in the research and development, production, sales and technical services of in vitro diagnostic reagents and supporting testing instruments; relying on independent innovation, A practical gene chip diagnostic technology platform has been formed, and its product line covers HPV, genetic diseases represented by thalassemia and other fields.


The Phase II study of Bristol-Myers Squibb's first-in-class oral TYK-2 inhibitor failed. On October 7, Bristol-Myers Squibb (BMS) announced that the first-in-class oral, selective TYK2 inhibitor Deucravacitinib for the treatment of moderate to severe ulcerative colitis (UC) phase II proof-of-concept LATTICE-UC study did not reach the 12th The primary endpoint of clinical remission at week, but also did not reach the secondary efficacy endpoint. The safety of Deucravacitinib is consistent with previously reported, and no new safety signals have been observed. BMS said that the company will complete a comprehensive review of the LATTICE-UC study data, and the potential of Deucvacitinib in UC will continue to be evaluated in the second phase II IM011-127 trial, which will include higher doses.


Biopharmaceutical company Oculis announced the establishment of a Hong Kong office and the appointment of its global chief medical officer. Oculis SA, a biopharmaceutical company focused on clinical development and research, announced the formal establishment of its Hong Kong office to enhance the company's future development and business capabilities in this important strategic region of China and Asia. Oculis improves and restores vision through the development of new ophthalmic treatments. In April of this year, Oculis completed a $57 million Series C financing. At the same time, Oculis announced the appointment of Dr. Chang Ruyu (Joanne Chang, M.D., Ph.D.) as the global chief medical officer and head of project portfolio management. She has worked for Novartis for 13 years, providing strategic guidance for ophthalmology businesses (including retina, gene therapy and anterior segment diseases). Prior to this, Dr. Ruyu Chang served as the head of clinical development and medical regulatory affairs for Alcon North America. She was the Chief Medical Officer and Vice President of Medical Affairs of Novartis Greater China. Before joining Novartis, Dr. Ruyu Chang held key positions in world-renowned pharmaceutical companies (including Bayer, Annett, Johnson & Johnson and Abbott Laboratories).


Northeast Pharmaceutical elected Guo Jianmin as the company's chairman. On October 8, Northeast Pharmaceutical issued an announcement stating that the company held the 58th meeting of the eighth board of directors on October 3. The meeting reviewed and passed the "Proposal on Election of the Company’s Eighth Board of Directors" and elected the company’s directors. Mr. Guo Jianmin serves as the chairman of the company, and his term of office is from the date of approval by the board of directors to the date when the new term of the board of directors is completed.


New trends in research and development


Andorra's first researched oral third-generation breast cancer new drug AND019 was approved for clinical use in the United States. The third-generation oral breast cancer class 1 new drug AND019, independently developed by Hangzhou Andao Pharmaceutical Co., Ltd., has been clinically approved by the US FDA. This is another innovative drug approved for global clinical development after the company's leading domestic new anemia drug AND017 was approved by the US FDA for Phase II clinical trials earlier this year. AND019 is an oral third-generation Selective Estrogen Receptor Degraders (SERDs) with a new chemical structure. The company owns the global intellectual property rights of the drug.

Share to:
Disclaimer: Echemi reserves the right of final explanation and revision for all the information.

Scan the QR Code to Share

Send Message